查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1863154

全球神经调控设备市场：洞察、竞争格局及市场预测（至2032年）

Neuromodulation Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

神经调控设备市场摘要

  • 全球神经调控设备市场预计将从 2024 年的 78.6204 亿美元成长到 2032 年的 161.111 亿美元，反映出强劲且持续的成长。
  • 全球神经调控设备市场在 2025 年至 2032 年的预测期内将以 9.44% 的复合年增长率成长。
  • 神经调控设备市场正经历快速成长，这主要得益于全球慢性疾病（如疼痛、癫痫和忧郁症）盛行率的上升。此外，技术的显着进步也推动了这一成长，使得设备体积更小、更强大、更智慧。有利的监管政策和完善的报销体係也提高了这些疗法的可及性。总而言之，对有效、长期治疗神经系统疾病和慢性疾病的方案日益增长的需求，正在催生一个强劲且可持续发展的市场。
  • 神经调节设备市场的主要企业包括：雅培实验室、史密斯医疗、贝朗医疗、百特国际、波士顿科学公司、LivaNova PLC、美敦力、Nevro公司、雅培、史赛克、欧姆龙公司、Stimwave LLC、皇家飞利浦公司、金佰利公司、EndoStimi. SA、Cyber​​onics、DyAnsys公司、NanoVibronix公司和ElectroCore公司。
  • 由于慢性疼痛和神经病变负担沉重、人们意识的提高、政府的支持计划、FDA 的频繁核准以及持续的产品创新，预计北美将继续保持其在神经调节设备市场的主导地位。
  • 在神经调节设备市场按设备类型分類的细分市场中，预计到 2024 年，脊髓刺激设备类别将占据最大的市场份额。

神经调控设备市场成长要素

  • 慢性病和神经系统疾病盛行率上升推动神经调控设备市场蓬勃发展：全球范围内，越来越多的疾病需要透过神经调控设备进行治疗，其中包括慢性疼痛、癫痫、帕金森氏症以及难治性忧郁症。随着这些疾病的日益普遍，对有效、长期治疗方案的需求也随之激增。
  • 技术进步：持续的技术创新正成为市场扩张的强大催化剂。近期趋势包括开发更小巧、更强大、可充电的设备，这些设备能够减轻手术负担、延长设备使用寿命并提高患者的便利性。诸如自适应深部脑部刺激等「闭合迴路」神经调控系统的出现，代表着模式转移，该系统能够即时监测神经活动，并仅在需要时进行刺激。这不仅提高了治疗效果，还最大限度地减少了副作用并优化了能量利用。此外，神经调控技术的应用范围不断扩大，涵盖了运动障碍以外的疾病，例如忧郁症、慢性疼痛、癫痫甚至睡眠障碍，这显着扩大了潜在市场。因此，疾病盛行率的不断上升，加上技术的快速发展，正在强化神经调控技术作为治疗复杂、长期神经系统疾病和慢性疾病的创新解决方案的作用。

患者和医疗专业人员都越来越倾向于选择微创治疗方法，这一趋势极大地推动了神经调控设备的应用。植入式神经调控手术通常被认为是治疗慢性疼痛、运动障碍和泌尿系统疾病的微创替代方案，优于传统手术。与开放性手术相比，植入式神经调控手术通常切口较小、住院时间更短、恢復更快、术后併发症更少，从而提高患者满意度并降低医疗成本。

除了这些手术操作的优势外，经皮植入技术、微型化导线和磁振造影相容设备等技术创新进一步降低了手术风险，并使更多患者能够接受这些手术。重要的是，微创神经调控在门诊和日间手术中也越来越受欢迎，这与医疗产业向以价值为导向的医疗和成本效益的转变相一致。随着许多市场的健保政策扩大到涵盖神经调控疗法，以及设备製造商不断改进治疗方式，预计这些干预措施的微创特性仍将是已开发国家和新兴医疗保健系统推广应用的关键驱动因素。

神经调控设备市场报告细分

本神经调控设备市场报告全面概​​述了全球神经调控设备市场，重点分析了关键趋势、成长驱动因素、挑战和机会。报告按设备类型、应用、最终用户和地区对市场进行了详细细分，并深入剖析了北美、欧洲和亚太等主要市场的竞争格局、监管环境和市场动态。报告详细介绍了行业领导者的概况和最新的产品创新，为企业提供了识别市场潜力、制定战略规划以及把握快速增长的神经调控设备市场新机会所需的重要数据。

神经调控设备是一种医疗技术，它透过刺激神经系统的特定区域来改变神经活动。这些刺激可以包括电讯号、磁场或化学物质。其目的是「调节」或使受疾病或损伤影响的神经组织功能恢復正常。

神经调控设备市场正经历显着成长，这主要得益于多种因素的共同作用。慢性疼痛、帕金森氏症、癫痫、自发性震颤等神经系统疾病以及难治性忧郁症等精神疾病在全球的日益普遍，是推动市场成长的主要因素。日益加重的疾病负担促使人们对有效且长期的治疗方案的需求不断增长。此外，技术的显着进步也使这些设备更加有效且易于使用。小型可充电植入、能够即时回应神经活动的「封闭回路型」系统以及经颅磁刺激 (TMS) 等非侵入性疗法的开发，都在不断扩大这些设备的应用范围。此外，更有利的法规环境和更完善的报销政策也使患者更容易获得这些治疗。这包括监管机构广泛核准神经刺激设备的新用途，以及保险公司提供更全面的保险覆盖。最后，全球人口老化以及与老龄化相关的神经系统疾病和慢性疼痛发病率的上升，进一步推动了市场的强劲成长。

根据发表在《柳叶刀神经病学》上的一项关于2021年全球疾病负担（GBD）研究的重要分析，2021年全球将有34亿人受到神经系统疾病的影响，占全球人口的43%。这使得神经系统疾病成为全球疾病和残疾的主要原因之一。其中最常见的疾病是紧张性头痛（影响约20亿人）和偏头痛（影响约11亿人）。神经调控设备，例如靶向枕神经的设备，透过阻断疼痛讯号，可以有效控制慢性头痛和偏头痛。此外，自1990年以来，糖尿病神经病变患者人数增加了两倍多，在2021年达到2.06亿。神经调控设备正越来越多地用于治疗神经损伤和相关疼痛。

根据世界卫生组织（世卫组织）的数据，全球约有5,000万人患有癫痫。神经调控装置，例如迷走神经刺激设备和反应性神经刺激设备，透过降低癫痫发作的频率和严重程度，为治疗提供了重要的选择，特别适用于药物难治性癫痫患者。

根据最新的GLOBOCAN 2022预测，全球将新增约2,000万例癌症病例，并有970万人死于癌症，五年患病人数将达5,350万人。最常见的癌症是肺癌（248万例）、乳癌（230万例）、大肠癌（193万例）、摄护腺癌（147万例）和胃癌（9.7万例）。整体而言，五分之一的人一生中会罹患癌症，九分之一的男性和十二分之一的女性会死于癌症。虽然高所得国家的癌症发生率较高，但由于早期检测和治疗机会有限，中低收入地区的癌症死亡率仍居高不下。展望未来，预计到2050年，全球癌症病例将增加至3,500万例，比2022年增加77%。许多癌症患者会经历神经病变疼痛，而这种疼痛通常难以透过常规治疗方法来控制。先进的神经调控设备正被用于为这些患者提供显着的疼痛缓解。

持续不断的新产品上市和监管核准是神经调控设备市场的主要驱动力。美敦力公司用于核准。与提供固定、连续刺激的传统DBS系统不同，aDBS平台能够即时监测患者的脑部活动，重点关注局部场电位（LFP）和β波振盪－帕金森氏症运动症状的生物标记。然后，它会根据患者在各种情况下（包括药物週期、休息和身体活动）的神经系统状态动态调整刺激参数。这项特性不仅提高了治疗的精准度，也减少了不必要的刺激，从而在最大限度减少运动障碍等副作用的同时，有望改善治疗效果。此外，BrainSense电极识别器的加入简化了编程，使临床医生能够更有效率地进行个人化治疗，为神经调控技术的发展树立了新的标竿。

主要的障碍在于设备和植入手术的高昂费用，这限制了患者的可及性，尤其是在开发中国家。训练有素的专业人员短缺加剧了这个问题，因为成功实施这种治疗方法需要一个专业的、多学科的团队，而缺乏此类专业知识可能导致患者疗效不佳。此外，神经调控设备被归类为高风险产品，导致核准流程漫长而复杂，可能会延缓创新产品的商业化进程。最后，患者和医生的犹豫也是一大障碍：患者可能担心接受侵入性手术，而一些医生可能更倾向于使用更传统、更熟悉的治疗方法，而不是神经调控。

神经调控设备市场細項分析 神经调控设备市场 - 依设备类型、应用、类型、最终用户、地区划分

脊髓刺激设备疗法主要受主流市场接受度的推动，预计2024年将占据全球神经调控设备市场份额的45%以上。世界卫生组织（WHO）（2023年）的数据显示，约有6.19亿人患有腰痛，预计到2050年这一数字将上升至8.43亿。同时，欧洲疼痛联盟（2023年）报告称，全球约有7.4亿人一生中至少会经历一次剧烈疼痛，其中近20%的人患有持续超过三个月的慢性疼痛。

脊髓刺激设备（SCS）作为治疗方法，正日益受到欢迎。 SCS透过向脊髓刺激设备输送靶向电脉衝，阻断疼痛讯号到达大脑，从而显着改善患者的治疗方法品质。

此外，美国国立卫生研究院 (NIH) 于 2023 年发表的一项研究表明，10% 至 40% 的患者在脊椎手术后会患上腰椎手术失败症候群 (FBSS)。随着椎间盘突出、脊椎狭窄和椎间盘退化性疾病等疾病的脊椎手术数量增加，FBSS 的盛行率也持续上升。由于重复手术风险高且往往无法提供持久的疼痛缓解，脊髓刺激设备正逐渐被认为是有效的替代方案。

2024 年 4 月，美敦力公司获得 FDA核准推出 Inceptiv™，这是首个闭环 SCS 系统，它利用即时生物回馈（诱发复合动作电位，ECAP）自动调节闭合迴路，即使在日常活动中也能保持最佳治疗效果。

2023年4月，百多力（Biotronik）的Prospera脊髓刺激系统获得FDA核准。该系统采用RESONANCE技术，这是首个多相刺激模式；同时还配备了Embrace One系统，这是一种以患者为中心的护理模式，可提供自动化、客观的日常远端核准、持续管理和支援。该系统还包括HomeStream远端系统管理、可充电植入，并相容于全身MRI成像。

这些进步都凸显了 SCS 市场的发展轨迹，即从需要定期在诊所进行调整的传统固定输出设备，转向强调远端照护、个人化和工作流程效率的智慧自适应系统。

疼痛管理领域将在神经调控设备市场占据主导地位，预计2024年将占全球销售额的58%左右。这一主导地位主要源自于慢性疼痛患者群体庞大且不断成长，对全球健康和经济带来了沉重负担。日益严重的鸦片类药物危机促使医疗保健领域发生重大转变，转向非成瘾性、无药物的替代疗法，例如神经调控。这些医疗设备正日益被视为安全有效的长期解决方案。包括脊髓刺激设备等更精密、更易于使用且更有效的设备在内的重大技术进步进一步强化了这一趋势。这些技术创新，加上有利的报销政策以及患者和医疗保健提供者日益增强的认知，正在巩固神经调控设备在疼痛管理领域的市场主导地位。

预计到2024年，由于临床疗效显着、应用广泛以及监管核准和报销机制的强力支持，侵入性神经调控设备将占据全球市场份额的85%以上。脊髓刺激设备、深层脑部刺激器、迷走神经刺激设备神经刺激器和荐骨神经刺激器等侵入性设备广泛用于治疗慢性疼痛、帕金森氏症、癫痫、忧郁症、尿失禁等疾病，其疗效已得到证实，赢得了医生和患者的信赖。

近年来，封闭回路型刺激、多相波形、小型化和磁振造影相容植入以及远端监测等技术的进步，进一步提升了安全性、有效性和易用性。慢性疼痛仍然是推动脊髓刺激器市场发展的主要因素，其中腰痛和腰椎手术失败症候群的日益普遍，进一步巩固了脊髓刺激设备的市场主导地位。此外，与因临床检验和应用有限而导致分散的非侵入性治疗领域不同，美敦力、雅培、波士顿科学、Nevro、百多力和Saluda等领先企业持续加强对侵入性治疗方案的投资。这些因素共同作用，预计2024年，侵入性神经调控设备将在全球市场占据主导地位。

预计到2024年，医院将继续主导神经调控设备市场，占据超过85%的市场份额，并在预测期内维持收入成长率和复合年增长率的主导地位。这一主导地位主要归功于医院作为复杂外科植入手术（例如脊髓刺激设备、深层脑部刺激器和迷走神经刺激设备）的主要中心，需要先进的基础设施、经验丰富的神经外科医生和多学科医疗团队。此外，医院还提供全面的术前评估、术中监测和术后康復，为患者和医生创造了良好的治疗环境。医院也受惠于完善的保险报销体系，使其能够实施更多高成本的植入式神经调控设备。慢性疼痛、神经病变和腰椎手术失败症候群日益严重的负担正在推动住院和手术量的增加，进一步促进了设备的使用。此外，技术的不断进步、与医疗技术公司的合作以及临床试验的参与，正在巩固医院作为神经调控治疗卓越中心的地位。相较之下，门诊中心和诊所虽然也在发展，但主要局限于后续观察治疗和非侵入性神经调控疗法，导致市占率不断萎缩。

根据美国疾病管制与预防中心（CDC，2023）的数据，2021年美国有20.9%的成年人（5,160万人）报告患有慢性疼痛，其中6.9%（1,710万人）患有严重慢性疼痛，影响日常生活。此外，约有290万成年人患有活动性癫痫（CDC，2024），阿兹海默症协会（2024）报告称，美国有690万65岁及以上的老年人患有阿兹海默症。帕金森氏症的盛行率也在上升，每年新增病例近9万例，现有病例超过100万例，预计2030年将达到120万例（帕金森基金会，2022）。

欧洲神经调控设备市场趋势

欧洲神经调控设备市场正蓬勃发展，规模仅次于北美，预计2024年将占据全球市场份额的约21%。这一增长主要受以下几个关键趋势驱动：慢性病盛行率上升和人口老化。这些趋势共同导致帕金森氏症、慢性疼痛和癫痫等疾病的患者群体不断扩大。技术进步也是重要的推动因素，市场上涌现越来越多的「智慧」封闭回路型系统以及小型可充电、非侵入式设备，这些设备能够改善患者的治疗效果和舒适度。此外，儘管监管和报销环境可能较为复杂，但许多欧洲主要国家已经建立了相应的框架来支援这些技术的应用。

亚太地区神经调控设备市场趋势

亚太地区正成为全球神经调控设备成长最快的市场，预计复合年增长率将超过12%。这一快速扩张是由该地区特有的趋势和动态所驱动的。

以下列出了神经调控设备市场的主要企业，它们总合占据最大的市场份额，并引领着行业趋势：

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.
  • 其他的

神经调控设备市场的竞争格局高度集中，少数几家大型企业，例如美敦力、雅培和波士顿科学，占据了市场主导地位。这些老牌企业凭藉着丰富的产品系列、强大的地域覆盖以及在研发方面的大量投入，维持着主导。竞争的核心在于技术进步，特别是开发体积更小、更便于患者使用且电池续航力更长的植入式设备，以及整合能够实现高阶程式设计和资料管理的软体平台。儘管市场高度集中于顶层企业，但也涌现出许多创新的小型公司和新兴企业，尤其是在非侵入式领域。这些新参与企业透过专注于细分应用和新技术，推动策略联盟和併购，挑战市场现状。

  • 2025 年 6 月，Neuspera Medical 的整合荐骨神经调节 (iSNM) 系统获得 FDA核准，用于治疗急性尿失禁(UUI)，无需植入电池，从而为患者提供更舒适的体验。
  • 2025 年 3 月，Neuronica 的下一代闭合迴路自适应 DBS 系统 AlphaDBS 获得了 CE 认证。
  • 2025 年 2 月，美国FDA核准了美敦力公司的 BrainSense 自适应深部脑部刺激 (aDBS) 系统。

神经调控设备市场细分

  • 神经调控设备市场趋势（依设备分类）
  • 脊髓刺激设备
  • 深层脑部刺激器
  • 荐骨神经刺激器
  • 迷走神经刺激设备
  • 其他的
  • 神经调控设备市场按应用领域分類的趋势
  • 疼痛管理
  • 尿失禁和粪便失禁
  • 神经系统疾病
  • 呼吸系统疾病
  • 其他的
  • 神经调控设备市场趋势（按类型划分）
  • 侵入性
  • 非侵入性
  • 神经调控设备市场最终用户趋势
  • 医院
  • 专科诊所
  • 其他的
  • 神经调控设备市场的区域趋势
  • 北美神经调控设备市场
  • 美国神经调控设备市场
  • 加拿大神经调控设备市场
  • 墨西哥神经调控设备市场
  • 欧洲神经调控设备市场
  • 英国神经调控设备市场
  • 德国神经调控设备市场
  • 法国神经调控设备市场
  • 义大利神经调控设备市场
  • 西班牙神经调控设备市场
  • 其他欧洲神经调控设备市场
  • 亚太地区神经调控设备市场
  • 中国神经调控设备市场
  • 日本神经调控设备市场
  • 印度神经调控设备市场
  • 澳洲神经调控设备市场
  • 韩国神经调控设备市场
  • 亚太地区其他神经调控设备市场
  • 世界其他地区神经调控设备市场
  • 南美洲神经调控设备市场
  • 中东神经调控设备市场
  • 非洲神经调控设备市场

利用人工智慧进行影响分析

人工智慧驱动的创新正在深刻地改变神经调控设备市场，推动该领域从「一刀切」的静态治疗转向高度个人化、动态和自适应的疗法。人工智慧的一项关键影响是闭合迴路系统的发展。与提供固定刺激的传统开环设备不同，人工智慧主导的设备能够利用来自神经活动、患者报告症状和生理指标的即时数据自动调整刺激参数。这不仅提高了治疗效果，还最大限度地减少了副作用和临床医生手动重新编程的负担。人工智慧演算法分析来自神经影像、患者病历和装置回馈的大量资料集，以预测治疗反应、优化电极放置，并创建患者大脑的个人化「数位孪生」模型，用于治疗方案模拟。这种向智慧、自主和响应式设备的转变正在推动下一代神经调控技术的发展，有望为慢性疼痛、运动障碍和精神疾病带来更有效、更精准、更以患者为中心的治疗方案。

这主要是由于医疗技术供应链的全球化，即使是美国製造的设备也常常依赖大量进口零件。因此，关税直接推高了製造成本，进而推高价格，并可能阻碍这些改变生命的技术的普及。这种情况也严重扰乱了供应链，迫使企业自行承担或转嫁成本，或透过供应商多元化或调整生产资源来彻底重组营运。虽然这可能为国内製造业带来策略机会，但也带来了巨大的不确定性和复杂性，对大型成熟企业和小型创新新兴企业都构成风险。最终，关税成为阻碍医疗保健产业关键领域的一大阻力。

目录

第一章 神经调控设备市场报告概述

  • 调查范围
  • 市场区隔
  • 市场假设

2. 神经调控设备市场执行摘要

  • 市场概览

第三章：神经调控设备市场关键因素分析

  • 市场驱动因素
    • 慢性病和神经系统疾病盛行率不断上升
    • 向微创手术过渡
    • 技术和创新方面的进步
    • 有利的监管和报销环境
  • 市场限制与挑战
    • 设备和手术高成本
    • 严格而复杂的法规结构
    • 手术相关的风险和併发症
    • 技术和可用性问题
  • 市场机会
    • 「智慧」与非侵入式科技的兴起

第四章 影响分析

  • 人工智慧驱动的创新和应用
  • 美国关税的影响分析

第五章 监理分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第六章 神经调控设备市场－波特五力分析

第七章 神经调控设备市场评估

  • 依设备类型
    • 脊髓刺激设备
    • 深层脑部刺激器
    • 荐骨神经刺激器
    • 迷走神经刺激设备
    • 其他的
  • 透过使用
    • 疼痛管理
    • 尿失禁和粪便失禁
    • 神经系统疾病
    • 呼吸系统疾病
  • 按类型
    • 侵入性
    • 非侵入性
  • 最终用户
    • 医院
    • 专科诊所
  • 地区
    • 北美洲
    • 欧洲
    • 亚太地区
    • 其他地区

第八章 竞争情势

第九章Start-Ups资金筹措与投资趋势

10. 神经调控设备市场中的公司与产品概况

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.

第十一章：KOL视角

第十二章计划方法

第十三章：关于 DelveInsight

第十四章 免责声明和联络我们

Product Code: DIMDCL0029

Neuromodulation Devices Market Summary

  • The global neuromodulation devices market is expected to increase from USD 7,862.04 million in 2024 to USD 16,111.10 million by 2032, reflecting strong and sustained growth.
  • The global neuromodulation devices market is growing at a CAGR of 9.44% during the forecast period from 2025 to 2032.
  • The market for neuromodulation devices is growing rapidly, fueled by the rising global prevalence of chronic diseases like pain, epilepsy, and depression. This growth is also driven by significant technological advancements that have made devices smaller, smarter, and more effective. Favorable regulatory policies and better reimbursement coverage are also making these treatments more accessible. Overall, the increasing demand for effective, long-term therapeutic options for neurological and chronic conditions is creating a strong and sustained market.
  • The leading companies operating in the neuromodulation devices market include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic, Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and Others.
  • North America is expected to remain a dominant force in the neuromodulation devices market, driven by the high burden of chronic pain and neurological disorders, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.
  • In the device type segment of the neuromodulation devices market, the spinal cord stimulators devices category is estimated to account for the largest market share in 2024.

Factors Contributing to the Growth of the Neuromodulation Devices Market

  • Rising Prevalence of Chronic and Neurological Disorders leading to a Surge in the Neuromodulation Devices Market: There is a growing global burden of conditions that neuromodulation devices are designed to treat. This includes the increasing incidence of chronic pain, epilepsy, Parkinson's disease, and treatment-resistant depression. As these conditions become more widespread, the demand for effective, long-term therapeutic solutions has surged.
  • Technological Advancements: continuous innovation is acting as a powerful catalyst for market expansion. Recent advances include the development of smaller, more powerful, and rechargeable devices, which reduce surgical burden and extend device lifespan, enhancing patient convenience. The emergence of "closed-loop" neuromodulation systems, such as adaptive deep brain stimulation, represents a paradigm shift by enabling real-time monitoring of neural activity and delivering stimulation only when required. This not only enhances therapeutic efficacy but also minimizes side effects and optimizes energy use. Moreover, the expanding application of neuromodulation in conditions beyond movement disorders, such as depression, chronic pain, epilepsy, and even sleep disorders, broadens the addressable market significantly. Collectively, the convergence of rising disease prevalence and rapid technological progress is reinforcing neuromodulation's role as a transformative solution in managing complex, long-term neurological and chronic conditions.

Shift Towards Minimally Invasive Procedures: Both patients and healthcare providers are increasingly favoring less invasive treatment options, a trend that strongly supports the adoption of neuromodulation devices. Implantable neuromodulation procedures are often regarded as a less invasive alternative to traditional surgeries for managing chronic pain, movement disorders, or urological conditions. Compared with open surgical interventions, they typically offer smaller incisions, shorter hospital stays, faster recovery times, and reduced postoperative complications, which translates into improved patient satisfaction and lower healthcare costs.

Beyond these procedural benefits, innovations such as percutaneous implantation techniques, miniaturized leads, and MRI-compatible devices have further reduced surgical risks while making these procedures more accessible to a broader patient population. Importantly, minimally invasive neuromodulation is also gaining traction in outpatient and ambulatory surgical settings, aligning with the healthcare industry's shift toward value-based care and cost efficiency. As reimbursement policies in many markets expand to include neuromodulation therapies, and as device manufacturers continue refining delivery methods, the less invasive nature of these interventions is expected to remain a major adoption driver across both developed and emerging healthcare systems.

Neuromodulation Devices Market Report Segmentation

This neuromodulation devices market report offers a comprehensive overview of the global neuromodulation devices market, highlighting key trends, growth drivers, challenges, and opportunities. It covers detailed market segmentation by by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and geography. The report provides valuable insights into the competitive landscape, regulatory environment, and market dynamics across major markets, including North America, Europe, and Asia-Pacific. Featuring in-depth profiles of leading industry players and recent product innovations, this report equips businesses with essential data to identify market potential, develop strategic plans, and capitalize on emerging opportunities in the rapidly growing neuromodulation devices market.

Neuromodulation devices are medical technologies that alter nerve activity by delivering a stimulus to specific areas of the nervous system. This stimulus can be electrical signals, magnetic fields, or chemical agents. The goal is to "modulate," or normalize, the function of nervous tissue that has been affected by disease or injury.

The market for neuromodulation devices is experiencing substantial growth, driven by a combination of factors. The rising global prevalence of chronic diseases such as chronic pain, neurological disorders like Parkinson's disease, epilepsy, and essential tremor, and mental health conditions like treatment-resistant depression is a primary driver. This increased disease burden has created a greater demand for effective, long-term therapeutic options. Furthermore, significant technological advancements have made these devices more effective and user-friendly. Innovations such as smaller, rechargeable implants, "closed-loop" systems that respond to neural activity in real time, and the development of non-invasive options like Transcranial Magnetic Stimulation (TMS) are expanding their adoption. Additionally, a more favorable regulatory environment and improved reimbursement policies are making these treatments more accessible to patients. This includes regulatory bodies approving a wider range of neurostimulators for new applications and insurers providing better coverage. Finally, the aging global population, which has a higher incidence of age-related neurological disorders and chronic pain, further contributes to the market's strong growth trajectory.

What are the latest Neuromodulation Devices Market Dynamics and Trends?

The growing market for neuromodulation devices is primarily driven by the escalating prevalence of various neurological conditions and the continuous introduction of innovative products by key industry players.

According to a major analysis from the Global Burden of Disease (GBD) Study 2021, published in The Lancet Neurology, neurological conditions collectively affected 3.4 billion people worldwide in 2021, representing 43% of the global population. This made them the leading cause of ill health and disability globally. The most prevalent of these conditions were tension-type headaches (affecting around 2 billion people) and migraines (affecting approximately 1.1 billion). Neuromodulation devices, such as those targeting the occipital nerves, are effective in managing chronic headaches and migraines by interrupting pain signals. Furthermore, the number of people with diabetic neuropathy has more than tripled since 1990, reaching 206 million in 2021, and neuromodulation devices are increasingly used to treat the nerve damage and associated pain.

The World Health Organization (WHO) reports that epilepsy affects around 50 million people globally. Neuromodulation devices like vagus nerve stimulators and responsive neurostimulators offer a critical treatment option, especially for patients with drug-resistant epilepsy, by reducing the frequency and severity of seizures.

The rise in cancer cases also contributes to the market. According to the latest GLOBOCAN 2022 estimates, there were about 20 million new cancer cases and 9.7 million deaths worldwide, with a 5-year prevalence of 53.5 million cases. The most common cancers were lung (2.48M cases), breast (2.30M), colorectal (1.93M), prostate (1.47M), and stomach (0.97M). Overall, 1 in 5 people will develop cancer during their lifetime, and 1 in 9 men and 1 in 12 women will die from it. While incidence is higher in high-income countries, mortality rates remain disproportionately high in low- and middle-income regions due to limited access to early detection and treatment. Looking ahead, global cancer cases are projected to rise to 35 million by 2050, a 77% increase from 2022. Many cancer patients experience neuropathic pain, which is often difficult to manage with conventional treatments. Advanced neuromodulation devices are being used to provide significant pain relief for these patients.

The continuous stream of new product introductions and regulatory approvals is a significant driver of the neuromodulation devices market. A notable example is the FDA approval in February 2025 of Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system for Parkinson's disease, the first adaptive or "closed-loop" DBS technology to reach the market. Unlike conventional DBS systems that deliver fixed, continuous stimulation, the aDBS platform monitors patients' brain activity in real time, focusing on local field potentials (LFPs) and beta-band oscillations, which are biomarkers of Parkinson's motor symptoms. The system then dynamically adjusts stimulation parameters to align with the patient's neurological state across various conditions, such as medication cycles, rest, and physical activity. This capability not only enhances therapeutic precision but also reduces unnecessary stimulation, potentially improving outcomes while minimizing side effects like dyskinesia. Moreover, the addition of the BrainSense Electrode Identifier simplifies programming and enables clinicians to personalize therapy more efficiently, setting a new benchmark in the evolution of brain modulation technologies.

The neuromodulation devices market faces significant restraints and challenges despite its growth. A primary obstacle is the high cost of both the devices and the surgical procedures required for implantation, which limits accessibility, particularly in developing countries. This issue is compounded by a shortage of trained professionals, as the successful application of this therapy requires a specialized, multidisciplinary team, and the lack of such expertise can lead to suboptimal patient outcomes. Furthermore, the market is constrained by stringent regulatory frameworks; neuromodulation devices are classified as high-risk, leading to a long and complex approval process that can delay the commercialization of new innovations. Finally, patient and physician hesitation also serves as a barrier. Patients may be apprehensive about undergoing an invasive surgery, while some physicians may lack awareness or prefer traditional, more familiar treatment methods over neuromodulation.

Neuromodulation Devices Market Segment Analysis

Neuromodulation Devices Market by Device Type (Spinal Cord Stimulators, Deep Brain Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, and Others), Application (Pain Management, Urinary & Faecal Incontinence, Neurological Disorders, Respiratory Disorders, and Others), Type (Invasive, Non-Invasive), End-Users (Hospitals, Specialty Clinics, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

By Device Type: Spinal Cord Stimulator Dominates the Market

The spinal cord stimulator category accounted for over 45% of the global neuromodulation devices market share in 2024, driven largely by mainstream adoption. According to the World Health Organization (2023), there were approximately 619 million cases of lower back pain (LBP), a figure expected to climb to 843 million by 2050. In parallel, the European Pain Federation (2023) reported that around 740 million people globally experience at least one episode of severe pain during their lifetime, with nearly 20% developing chronic pain lasting more than three months. This growing burden of chronic pain highlights the urgent need for effective and sustainable pain management solutions.

Spinal cord stimulators (SCS) have gained traction as they provide a minimally invasive, drug-free, and reversible therapy option. By delivering targeted electrical impulses to the spinal cord, these devices block pain signals before they reach the brain, significantly improving patient quality of life. The rising incidence of chronic pain disorders is, therefore, expected to be a major driver of SCS adoption worldwide.

Furthermore, findings published by the NIH (2023) revealed that Failed Back Surgery Syndrome (FBSS) affects 10-40% of patients following spinal surgeries. With the growing volume of spinal procedures for conditions such as herniated discs, spinal stenosis, and degenerative disc disease, the prevalence of FBSS continues to rise. Since repeated surgeries carry higher risks and often fail to deliver lasting pain relief, spinal cord stimulators are increasingly being recognized as an effective alternative. Their ability to reduce dependency on opioids, improve functional outcomes, and lower long-term healthcare costs makes them a preferred treatment choice, particularly for patients with FBSS and chronic neuropathic pain.

Emerging regulatory approvals are catalyzing market growth by enabling easier access to advanced SCS technologies:

In April 2024, Medtronic gained FDA approval for Inceptiv(TM), the first closed-loop SCS system to automatically adjust stimulation using real-time biological feedback (evoked compound action potentials, or ECAPs), maintaining optimal therapy even during daily movement. It is also the only FDA-approved closed-loop system offering full-body 3T MRI access with no restrictions, and is touted as the smallest and thinnest fully implantable SCS device.

In April 2023, Biotronik received FDA approval for its Prospera SCS System, featuring RESONANCE, the first multiphase stimulation paradigm, and Embrace One, a patient-centric care model offering automatic, objective, daily remote monitoring, ongoing management, and support. The system also includes HomeStream remote management, rechargeable implants, and full-body MRI compatibility

Each of these advancements highlights the trajectory of the SCS market, shifting from traditional, fixed-output devices requiring routine in-clinic adjustments, to intelligent, adaptive systems that emphasize remote care, personalization, and workflow efficiency.

By Application: Pain Management Categroy Dominate the Market

The pain management segment dominates the neuromodulation devices market, contributing nearly 58% of global revenue in 2024. This domicance is primarily due to the vast and growing population suffering from chronic pain, a condition that poses a significant global health and economic burden. The escalating opioid crisis has propelled a major shift in healthcare, favoring non-addictive, drug-free alternatives like neuromodulation. These devices are increasingly seen as a safe and effective long-term solution. This trend is further amplified by significant technological advancements, including the development of more sophisticated, user-friendly, and effective devices such as spinal cord stimulators. These innovations, coupled with favorable reimbursement policies and increasing awareness among both patients and healthcare providers, have solidified pain management's leading position in the market.

By Type: Invasive Categroy Dominate the Market

In 2024, the invasive neuromodulation devices category accounted for over 85% of the global market share due to their established clinical effectiveness, broad adoption, and strong support from regulatory approvals and reimbursement frameworks. Invasive devices such as spinal cord stimulators, deep brain stimulators, vagus nerve stimulators, and sacral nerve stimulators are widely used for chronic pain, Parkinson's disease, epilepsy, depression, and urinary incontinence, with proven outcomes that drive physician and patient confidence.

Recent technological advancements, including closed-loop stimulation, multiphase waveforms, miniaturized and MRI-compatible implants, and remote monitoring, have further enhanced their safety, efficacy, and usability. Chronic pain remains the largest driver, with spinal cord stimulators dominating given the rising prevalence of lower back pain and failed back surgery syndrome. Additionally, major players such as Medtronic, Abbott, Boston Scientific, Nevro, Biotronik, and Saluda continue to invest heavily in invasive solutions, unlike the fragmented non-invasive segment, which remains limited by narrower clinical validation and adoption. Together, these factors solidified the dominance of invasive neuromodulation devices in the global market in 2024.

By End-Users: Hospitals Dominate the Market

Hospitals dominated the global neuromodulation devices market in 2024, accounting for over 85% of the market share, and are expected to maintain leadership in terms of both revenue growth and CAGR during the forecast period. This dominance stems from the fact that hospitals serve as the primary centers for conducting complex surgical implantations of devices such as spinal cord stimulators, deep brain stimulators, and vagus nerve stimulators, which require advanced infrastructure, skilled neurosurgeons, and multidisciplinary care teams. Hospitals also provide comprehensive pre-operative evaluation, intraoperative monitoring, and post-operative rehabilitation, making them the preferred treatment setting for both patients and physicians. Furthermore, hospitals benefit from better reimbursement frameworks, enabling greater adoption of high-cost implantable neuromodulation devices. The rising burden of chronic pain, neurological disorders, and failed back surgery syndrome has increased hospital admissions and surgical volumes, further driving utilization. In addition, continuous technological upgrades, partnerships with MedTech companies, and participation in clinical trials strengthen hospitals' role as the central hubs for neuromodulation therapies. In contrast, outpatient centers and clinics, while growing, are largely limited to follow-up care or non-invasive neuromodulation, which contributes to their smaller market share. These factors collectively explain why hospitals remain the dominant end user in the neuromodulation devices market.

Neuromodulation Devices Market Regional Analysis

North America Neuromodulation Devices Market Trends

North America, led by the U.S., accounted for a dominant ~55% share of the global neuromodulation devices market in 2024, due to a combination of factors that create a highly favorable environment for the development, adoption, and commercialization of these technologies.

According to the CDC (2023), in 2021, 20.9% of U.S. adults (51.6M) reported chronic pain, with 6.9% (17.1M) experiencing high-impact chronic pain that limits daily activities. Additionally, around 2.9 million adults were living with active epilepsy (CDC, 2024), while the Alzheimer's Association (2024) reported 6.9 million Americans aged 65+ with Alzheimer's disease. Parkinson's disease prevalence is also rising, with nearly 90,000 new cases annually and over 1 million people affected, expected to reach 1.2 million by 2030 (Parkinson's Foundation, 2022).

Europe Neuromodulation Devices Market Trends

The neuromodulation devices market in Europe is dynamic and expanding, ranking second only to North America and accounting for approximately 21% of the global market share in 2024. This growth is driven by several key trends, including the rising prevalence of chronic conditions and an aging population, which together create a significant patient pool for conditions like Parkinson's disease, chronic pain, and epilepsy. Technological advancements are also a major catalyst, with the market seeing a rise in "smart," closed-loop systems, as well as smaller, rechargeable, and non-invasive devices that improve patient outcomes and comfort. Furthermore, while the regulatory and reimbursement landscape can be complex, many major European countries have established frameworks that support the adoption of these technologies. This growth is further propelled by the strong presence of global industry leaders, which drives continuous innovation and new product launches in the region.

Asia-Pacific Neuromodulation Devices Market Trends

The Asia-Pacific region is emerging as the fastest-growing market for neuromodulation devices globally, with a projected compound annual growth rate (CAGR) of over 12%. This rapid expansion is driven by a unique set of regional trends and dynamics.

Who are the major players in the Neuromodulation Devices Market?

The following are the leading companies in the Neuromodulation Devices market. These companies collectively hold the largest market share and dictate industry trends.

  • Abbott Laboratories
  • Smith's Medical
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boston Scientific Corp.
  • LivaNova PLC.
  • Medtronic
  • Nevro Corp.
  • Abbott
  • Stryker
  • Omron Corporation
  • Stimwave LLC
  • Koninklijke Philips NV
  • Kimberly Clark Corporation
  • EndoStim Inc.
  • Aleva neurotherapeutics SA
  • Cyberonics
  • DyAnsys, Inc.
  • NanoVibronix, Inc.
  • ElectroCore Inc.
  • Others

How is the competitive landscape shaping the neuromodulation devices market?

The competitive landscape of the neuromodulation devices market is characterized by a high degree of concentration, with a few major players, namely Medtronic, Abbott Laboratories, and Boston Scientific, holding a dominant market share. These established companies maintain their lead through extensive product portfolios, strong geographical presence, and significant investments in research and development. The competition is shaping around technological advancements, particularly in developing smaller, more patient-friendly implantable devices with longer battery life, and integrating software platforms that allow for advanced programming and data management. While the market is highly concentrated at the top, it is also seeing an influx of innovative, smaller companies and startups, particularly in the non-invasive segment. These new entrants are focusing on niche applications and new technologies to challenge the status quo, driving strategic partnerships, mergers, and acquisitions as larger players seek to broaden their product offerings and stay ahead in this rapidly evolving field.

Recent Developmental Activities in the Neuromodulation Devices Market

  • In June 2025, Neuspera Medical's integrated sacral neuromodulation (iSNM) system received FDA approval to treat urinary urge incontinence (UUI) with no implantable battery, offering a more comfortable patient experience.
  • In March 2025, Newronika's AlphaDBS, a next-generation closed-loop adaptive DBS system, received CE Mark.
  • In February 2025, the U.S. FDA has approved Medtronic's BrainSense Adaptive Deep Brain Stimulation (aDBS) system, which is the first of its kind for treating Parkinson's disease.

Neuromodulation Devices Market Segmentation

  • Neuromodulation Devices Device Type Exposure
  • Spinal Cord Stimulators
  • Deep Brain Stimulators
  • Sacral Nerve Stimulators
  • Vagus Nerve Stimulators
  • Others
  • Neuromodulation Devices Application Exposure
  • Pain Management
  • Urinary & Faecal Incontinence
  • Neurological Disorders
  • Respiratory Disorders
  • Others
  • Neuromodulation Devices Type Exposure
  • Invasive
  • Non-Invasive
  • Neuromodulation Devices End-Users Exposure
  • Hospitals
  • Specialty Clinics
  • Others
  • Neuromodulation Devices Geography Exposure
  • North America Neuromodulation Devices Market
  • United States Neuromodulation Devices Market
  • Canada Neuromodulation Devices Market
  • Mexico Neuromodulation Devices Market
  • Europe Neuromodulation Devices Market
  • United Kingdom Neuromodulation Devices Market
  • Germany Neuromodulation Devices Market
  • France Neuromodulation Devices Market
  • Italy Neuromodulation Devices Market
  • Spain Neuromodulation Devices Market
  • Rest of Europe Neuromodulation Devices Market
  • Asia-Pacific Neuromodulation Devices Market
  • China Neuromodulation Devices Market
  • Japan Neuromodulation Devices Market
  • India Neuromodulation Devices Market
  • Australia Neuromodulation Devices Market
  • South Korea Neuromodulation Devices Market
  • Rest of Asia-Pacific Neuromodulation Devices Market
  • Rest of the World Neuromodulation Devices Market
  • South America Neuromodulation Devices Market
  • Middle East Neuromodulation Devices Market
  • Africa Neuromodulation Devices Market

Impact Analysis

AI-Powered Innovations and Applications:

AI-powered innovations are profoundly transforming the neuromodulation devices market, moving the field from "one-size-fits-most" static therapies to highly personalized, dynamic, and adaptive treatments. The primary impact of AI is the development of closed-loop systems. Unlike traditional open-loop devices that deliver a fixed stimulus, AI-driven devices use real-time data from neural activity, patient-reported symptoms, and physiological markers to automatically adjust stimulation parameters. This not only enhances therapeutic efficacy but also minimizes side effects and the burden on clinicians for manual reprogramming. AI algorithms analyze vast datasets from neuroimaging, patient history, and device feedback to predict treatment responses, optimize electrode placement, and create personalized "digital twins" of a patient's brain for simulated therapy planning. This shift towards intelligent, autonomous, and responsive devices is driving the next generation of neuromodulation, promising a future of more effective, precise, and patient-centric therapies for chronic pain, movement disorders, and psychiatric conditions.

U.S. Tariff Impact Analysis on the Neuromodulation Devices Market:

The implementation of U.S. tariffs on medical device components is creating significant challenges for the neuromodulation devices market. This is mainly due to the globalized supply chains of medical technology, where even devices manufactured in the U.S. often rely on a substantial number of imported parts. As a result, the tariffs are directly increasing manufacturing costs, which in turn puts pressure on pricing and could potentially hinder the adoption of these life-changing technologies. This situation is also causing major supply chain disruptions, forcing companies to either absorb the costs, pass them on, or completely restructure their operations by diversifying suppliers or even reshoring production. While this may offer a strategic opportunity for domestic manufacturing, it simultaneously introduces significant uncertainty and complexity, posing a risk to both large, established companies and smaller, innovative startups. Ultimately, the tariffs are a major headwind that threatens to slow down a crucial sector of the healthcare industry.

How This Analysis Helps Clients

  • Cost Management: By understanding the tariff landscape, clients can anticipate cost increases and adjust pricing strategies accordingly, ensuring profitability.
  • Supply Chain Optimization: Clients can identify alternative sourcing options and diversify their supply chains to reduce dependency on high-tariff regions, enhancing resilience.
  • Regulatory Navigation: Expert guidance on navigating the evolving regulatory environment helps clients maintain compliance and avoid potential legal challenges.
  • Strategic Planning: Insights into tariff impacts enable clients to make informed decisions about manufacturing locations, partnerships, and market entry strategies.

Key takeaways from the neuromodulation devices market report study

  • Market size analysis for the current neuromodulation devices market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the neuromodulation devices market.
  • Various opportunities available for the other competitors in the neuromodulation devices market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current neuromodulation devices market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for the neuromodulation devices market growth in the future?

Frequently Asked Questions for the Neuromodulation Devices Market

1. What is the growth rate of the neuromodulation devices market?

  • The neuromodulation devices market is estimated to grow at a CAGR of 9.44% during the forecast period from 2025 to 2032.

2. What is the market for neuromodulation devices?

  • The neuromodulation devices market was valued at USD 7,862.04 million in 2024, and is expected to reach USD 16,111.10 million by 2032.

3. Which region has the highest share in the neuromodulation devices market?

  • North America is expected to remain a dominant force in the neuromodulation devices market, driven by the high burden of chronic pain and neurological disorders, increasing awareness initiatives, supportive government programs, and continuous product innovations with frequent FDA approvals.

4. What are the drivers for the neuromodulation devices market?

  • The market for neuromodulation devices is growing rapidly, fueled by the rising global prevalence of chronic diseases like pain, epilepsy, and depression. This growth is also driven by significant technological advancements that have made devices smaller, smarter, and more effective. Favorable regulatory policies and better reimbursement coverage are also making these treatments more accessible. Overall, the increasing demand for effective, long-term therapeutic options for neurological and chronic conditions is creating a strong and sustained market.

5. Who are the key players operating in the neuromodulation devices market?

  • Some of the key market players operating in the neuromodulation devices market include Abbott Laboratories, Smith's Medical, B. Braun Melsungen AG, Baxter International Inc., Boston Scientific Corp., LivaNova PLC., Medtronic, Nevro Corp., Abbott, Stryker, Omron Corporation, Stimwave LLC, Koninklijke Philips NV, Kimberly Clark Corporation, EndoStim Inc., Aleva neurotherapeutics SA, Cyberonics, DyAnsys, Inc., NanoVibronix, Inc., ElectroCore Inc., and Others.

Table of Contents

1. Neuromodulation Devices Market Report Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Segmentation
  • 1.3 Market Assumption

2. Neuromodulation Devices Market Executive Summary

  • 2.1 Market at Glance

3. Neuromodulation Devices Market Key Factors Analysis

  • 3.1 Neuromodulation Devices Market Drivers
    • 3.1.1 Rising Prevalence of Chronic and Neurological Disorders
    • 3.1.2 Shift Towards Minimally invasive Procedures
    • 3.1.3 Advancements in Technology and Innovation
    • 3.1.4 Favorable Regulatory and Reimbursement Landscape
  • 3.2 Neuromodulation Devices Market Restraints and Challenges
    • 3.2.1 High Cost of Devices and Procedures
    • 3.2.2 Stringent and Complex Regulatory Frameworks
    • 3.2.3 Risks and Complications Associated with Surgery
    • 3.2.4 Technical and Usability Issues
  • 3.3 Neuromodulation Devices Market Opportunity
    • 3.3.1 Rise of "Smart" and Non-Invasive Technologies

4. Impact Analysis

  • 4.1 AI-Powered Innovations and Applications
  • 4.2 U.S. Tariff Impact Analysis

5. Regulatory Analysis

  • 5.1 The United States
  • 5.2 Europe
  • 5.3 Japan
  • 5.4 China

6. Neuromodulation Devices Market Porter's Five Forces Analysis

  • 6.1 Bargaining Power of Suppliers
  • 6.2 Bargaining Power of Consumers
  • 6.3 Threat of New Entrants
  • 6.4 Threat of Substitutes
  • 6.5 Competitive Rivalry

7. Neuromodulation Devices Market Assessment

  • 7.1 By Device Type
    • 7.1.1 Spinal Cord Stimulators
    • 7.1.2 Deep Brain Stimulators
    • 7.1.3 Sacral Nerve Stimulators
    • 7.1.4 Vagus Nerve Stimulators
    • 7.1.5 Others
  • 7.2 By Application
    • 7.2.1 Pain Management
    • 7.2.2 Urinary & Faecal Incontinence
    • 7.2.3 Neurological Disorders
    • 7.2.4 Respiratory Disorders
    • 7.2.5 Others
  • 7.3 By Type
    • 7.3.1 Invasive
    • 7.3.2 Non-Invasive
  • 7.4 By End-Users
    • 7.4.1 Hospitals
    • 7.4.2 Specialty Clinics
    • 7.4.3 Others
  • 7.5 By Geography
    • 7.5.1 North America
      • 7.5.1.1 United States Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.1.2 Canada Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.1.3 Mexico Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.2 Europe
      • 7.5.2.1 France Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.2 Germany Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.3 United Kingdom Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.4 Italy Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.5 Spain Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.2.6 Rest of Europe Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.3 Asia-Pacific
      • 7.5.3.1 China Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.2 Japan Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.3 India Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.4 Australia Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.5 South Korea Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.3.6 Rest of Asia-Pacific Neuromodulation Devices Market Size in USD million (2022-2032)
    • 7.5.4 Rest of the World (RoW)
      • 7.5.4.1 Middle East Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.4.2 Africa Neuromodulation Devices Market Size in USD million (2022-2032)
      • 7.5.4.3 South America Neuromodulation Devices Market Size In USD Million (2022-2032)

8. Competitive Landscape

9. Startup Funding & Investment Trends

10. Neuromodulation Devices Market Company and Product Profiles

  • 10.1 Abbott Laboratories
    • 10.1.1 Company Overview
    • 10.1.2 Company Snapshot
    • 10.1.3 Financial Overview
    • 10.1.4 Product Listing
    • 10.1.5 Entropy
  • 10.2 Smith's Medical
    • 10.2.1 Company Overview
    • 10.2.2 Company Snapshot
    • 10.2.3 Financial Overview
    • 10.2.4 Product Listing
    • 10.2.5 Entropy
  • 10.3 B. Braun Melsungen AG
    • 10.3.1 Company Overview
    • 10.3.2 Company Snapshot
    • 10.3.3 Financial Overview
    • 10.3.4 Product Listing
    • 10.3.5 Entropy
  • 10.4 Baxter International Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Snapshot
    • 10.4.3 Financial Overview
    • 10.4.4 Product Listing
    • 10.4.5 Entropy
  • 10.5 Boston Scientific Corp.
    • 10.5.1 Company Overview
    • 10.5.2 Company Snapshot
    • 10.5.3 Financial Overview
    • 10.5.4 Product Listing
    • 10.5.5 Entropy
  • 10.6 LivaNova PLC.
    • 10.6.1 Company Overview
    • 10.6.2 Company Snapshot
    • 10.6.3 Financial Overview
    • 10.6.4 Product Listing
    • 10.6.5 Entropy
  • 10.7 Medtronic
    • 10.7.1 Company Overview
    • 10.7.2 Company Snapshot
    • 10.7.3 Financial Overview
    • 10.7.4 Product Listing
    • 10.7.5 Entropy
  • 10.8 Nevro Corp.
    • 10.8.1 Company Overview
    • 10.8.2 Company Snapshot
    • 10.8.3 Financial Overview
    • 10.8.4 Product Listing
    • 10.8.5 Entropy
  • 10.9 Abbott
    • 10.9.1 Company Overview
    • 10.9.2 Company Snapshot
    • 10.9.3 Financial Overview
    • 10.9.4 Product Listing
    • 10.9.5 Entropy
  • 10.10 Stryker
    • 10.10.1 Company Overview
    • 10.10.2 Company Snapshot
    • 10.10.3 Financial Overview
    • 10.10.4 Product Listing
    • 10.10.5 Entropy
  • 10.11 Omron Corporation
    • 10.11.1 Company Overview
    • 10.11.2 Company Snapshot
    • 10.11.3 Financial Overview
    • 10.11.4 Product Listing
    • 10.11.5 Entropy
  • 10.12 Stimwave LLC
    • 10.12.1 Company Overview
    • 10.12.2 Company Snapshot
    • 10.12.3 Financial Overview
    • 10.12.4 Product Listing
    • 10.12.5 Entropy
  • 10.13 Koninklijke Philips NV
    • 10.13.1 Company Overview
    • 10.13.2 Company Snapshot
    • 10.13.3 Financial Overview
    • 10.13.4 Product Listing
    • 10.13.5 Entropy
  • 10.14 Kimberly Clark Corporation
    • 10.14.1 Company Overview
    • 10.14.2 Company Snapshot
    • 10.14.3 Financial Overview
    • 10.14.4 Product Listing
    • 10.14.5 Entropy
  • 10.15 EndoStim Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Snapshot
    • 10.15.3 Financial Overview
    • 10.15.4 Product Listing
    • 10.15.5 Entropy
  • 10.16 Aleva neurotherapeutics SA
    • 10.16.1 Company Overview
    • 10.16.2 Company Snapshot
    • 10.16.3 Financial Overview
    • 10.16.4 Product Listing
    • 10.16.5 Entropy
  • 10.17 Cyberonics
    • 10.17.1 Company Overview
    • 10.17.2 Company Snapshot
    • 10.17.3 Financial Overview
    • 10.17.4 Product Listing
    • 10.17.5 Entropy
  • 10.18 DyAnsys, Inc.
    • 10.18.1 Company Overview
    • 10.18.2 Company Snapshot
    • 10.18.3 Financial Overview
    • 10.18.4 Product Listing
    • 10.18.5 Entropy
  • 10.19 NanoVibronix, Inc.
    • 10.19.1 Company Overview
    • 10.19.2 Company Snapshot
    • 10.19.3 Financial Overview
    • 10.19.4 Product Listing
    • 10.19.5 Entropy
  • 10.20 ElectroCore Inc.
    • 10.20.1 Company Overview
    • 10.20.2 Company Snapshot
    • 10.20.3 Financial Overview
    • 10.20.4 Product Listing
    • 10.20.5 Entropy

11. KOL Views

12. Project Approach

13. About DelveInsight

14. Disclaimer & Contact Us

List of Tables

  • Table 1: Neuromodulation Devices Market in Global (2022-2032)
  • Table 2: Neuromodulation Devices Market in Global by Device Type (2022-2032)
  • Table 3: Neuromodulation Devices Market in Global by Application (2022-2032)
  • Table 4: Neuromodulation Devices Market in Global by Type (2022-2032)
  • Table 5: Neuromodulation Devices Market in Global by End-Users (2022-2032)
  • Table 6: Neuromodulation Devices Market in Global by Geography (2022-2032)
  • Table 7: Neuromodulation Devices Market in North America (2022-2032)
  • Table 8: Neuromodulation Devices Market in the United States (2022-2032)
  • Table 9: Neuromodulation Devices Market in Canada (2022-2032)
  • Table 10: Neuromodulation Devices Market in Mexico (2022-2032)
  • Table 11: Neuromodulation Devices Market in Europe (2022-2032)
  • Table 12: Neuromodulation Devices Market in France (2022-2032)
  • Table 13: Neuromodulation Devices Market in Germany (2022-2032)
  • Table 14: Neuromodulation Devices Market in United Kingdom (2022-2032)
  • Table 15: Neuromodulation Devices Market in Italy (2022-2032)
  • Table 16: Neuromodulation Devices Market in Spain (2022-2032)
  • Table 17: Neuromodulation Devices Market in the Rest of Europe (2022-2032)
  • Table 18: Neuromodulation Devices Market in Asia-Pacific (2022-2032)
  • Table 19: Neuromodulation Devices Market in China (2022-2032)
  • Table 20: Neuromodulation Devices Market in Japan (2022-2032)
  • Table 21: Neuromodulation Devices Market in India (2022-2032)
  • Table 22: Neuromodulation Devices Market in Australia (2022-2032)
  • Table 23: Neuromodulation Devices Market in South Korea (2022-2032)
  • Table 24: Neuromodulation Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Neuromodulation Devices Market in the Rest of the World (2022-2032)
  • Table 26: Neuromodulation Devices Market in the Middle East (2022-2032)
  • Table 27: Neuromodulation Devices Market in Africa (2022-2032)
  • Table 28: Neuromodulation Devices Market in South America (2022-2032)
  • Table 29: Competitive Landscape
  • Table 30: Startup Funding & Investment Trends

List of Figures

  • Table 1: Neuromodulation Devices Market Drivers
  • Table 2: Neuromodulation Devices Market Restraints
  • Table 3: Neuromodulation Devices Market Opportunities
  • Table 4: AI-Powered Innovations in Neuromodulation Devices Market
  • Table 5: US Tariff Impact on Neuromodulation Devices Market
  • Table 6: Regulatory Analysis (US, EU, Japan, China)
  • Table 7: Porter's Five Forces Analysis
  • Table 8: Competitive Analysis
  • Table 9: Neuromodulation Devices Market in Global (2022-2032)
  • Table 10: Neuromodulation Devices Market in Global by Device Type (2022-2032)
  • Table 11: Neuromodulation Devices Market in Global by Application (2022-2032)
  • Table 12: Neuromodulation Devices Market in Global by Type (2022-2032)
  • Table 13: Neuromodulation Devices Market in Global by End-Users (2022-2032)
  • Table 14: Neuromodulation Devices Market in Global by Geography (2022-2032)
  • Table 15: Neuromodulation Devices Market in North America (2022-2032)
  • Table 16: Neuromodulation Devices Market in the United States (2022-2032)
  • Table 17: Neuromodulation Devices Market in Canada (2022-2032)
  • Table 18: Neuromodulation Devices Market in Mexico (2022-2032)
  • Table 19: Neuromodulation Devices Market in Europe (2022-2032)
  • Table 20: Neuromodulation Devices Market in France (2022-2032)
  • Table 21: Neuromodulation Devices Market in Germany (2022-2032)
  • Table 22: Neuromodulation Devices Market in United Kingdom (2022-2032)
  • Table 23: Neuromodulation Devices Market in Italy (2022-2032)
  • Table 24: Neuromodulation Devices Market in Spain (2022-2032)
  • Table 25: Neuromodulation Devices Market in the Rest of Europe (2022-2032)
  • Table 26: Neuromodulation Devices Market in Asia-Pacific (2022-2032)
  • Table 27: Neuromodulation Devices Market in China (2022-2032)
  • Table 28: Neuromodulation Devices Market in Japan (2022-2032)
  • Table 29: Neuromodulation Devices Market in India (2022-2032)
  • Table 30: Neuromodulation Devices Market in Australia (2022-2032)
  • Table 31: Neuromodulation Devices Market in South Korea (2022-2032)
  • Table 32: Neuromodulation Devices Market in Rest of Asia-Pacific (2022-2032)
  • Table 33: Neuromodulation Devices Market in the Rest of the World (2022-2032)
  • Table 34: Neuromodulation Devices Market in the Middle East (2022-2032)
  • Table 35: Neuromodulation Devices Market in Africa (2022-2032)
  • Table 36: Neuromodulation Devices Market in South America (2022-2032)
  • Table 37: Competitive Landscape
  • Table 38: Startup Funding & Investment Trends